[lcus_masonry_article] Case Study: A Mid-Tier Pharma Uses a 300-Disease Package to Prioritize and Out-License A mid-tier pharmaceutical company wanted to expand its early pipeline without running 300 separate discovery programs. They were interested in a single, structured research package that covered many indications with a consistent methodology—compound analysis, synthesis methods, biological mechanism documentation—so they could […]
content by LCUS
Product Insight – 300 Diseases One Methodology, How to Evaluate a Portfolio Handoff
[lcus_masonry_article] Product Insight: 300 Diseases, One Methodology—How to Evaluate a Portfolio Handoff The 300 Disease Cure Research product is not 300 separate deals. It is one research package: 300 diseases, each with compound analysis, synthesis methods, and biological mechanism documentation, all under a consistent Alchemy Data methodology and cure-focused framing. The product insight is how […]